Mead Emma J, Chiverton Lesley M, Smales C Mark, von der Haar Tobias
Department of Biosciences, University of Kent, Canterbury, UK.
Biotechnol Bioeng. 2009 Apr 15;102(6):1593-602. doi: 10.1002/bit.22201.
Mammalian cell lines are currently employed as one of the main cellular factories for the expression of recombinant protein-based drugs. The establishment of high-producing cell lines typically begins with a heterogeneous starter population of cells, from which the highest producing cells are selected via empirical approaches. This approach is time consuming, and is likely to encounter natural upper limits imposed by the inherent biology of the cell lines in question. In an attempt to understand both the nature of the variability in populations of cells transfected with recombinant protein encoding DNA and the natural mechanisms of productivity limitation, we developed protocols for the detailed investigation of gene expression pathways in such cell lines. This novel approach was then applied to a set of clonal CHOK1 cell lines producing recombinant luciferase with varying productivities. Our results show that the initial limitation in these cell lines is at the transcriptional level, however in the highest producing cell line post-translational mechanisms affecting both protein turnover and protein folding become severely limiting. The implications for the development of strategies to engineer cells for enhanced recombinant protein production levels are discussed.
哺乳动物细胞系目前被用作表达基于重组蛋白的药物的主要细胞工厂之一。高产细胞系的建立通常始于细胞的异质起始群体,通过经验方法从中选择产量最高的细胞。这种方法耗时且可能会遇到所讨论细胞系固有生物学特性所施加的自然上限。为了理解用编码重组蛋白的DNA转染的细胞群体中变异性的本质以及生产力限制的自然机制,我们开发了详细研究此类细胞系中基因表达途径的方案。然后将这种新方法应用于一组产生具有不同生产力的重组荧光素酶的克隆CHOK1细胞系。我们的结果表明,这些细胞系中的初始限制在转录水平,然而在产量最高的细胞系中,影响蛋白质周转和蛋白质折叠的翻译后机制变得严重受限。讨论了对设计细胞以提高重组蛋白生产水平的策略开发的影响。